Is AYTU BIOPHARMA, INC (AYTU) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 80.7% / 30% | 114.4% / 30% | 115.2% / 30% | 18.95% / 5% | ✗ NOT HALAL |
| DJIM | 80.7% / 33% | 114.4% / 33% | 115.2% / 33% | 18.95% / 5% | ✗ NOT HALAL |
| MSCI | 17.6% / 33% | 24.9% / 33% | 25.1% / 33% | 18.95% / 5% | ✗ NOT HALAL |
| S&P | 80.7% / 33% | 114.4% / 33% | 115.2% / 33% | 18.95% / 5% | ✗ NOT HALAL |
| FTSE | 17.6% / 33% | 24.9% / 33% | 25.1% / 50% | 18.95% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 66.8% | |
| Operating Margin | -13.0% | |
| Net Margin | -39.0% | |
| Return on Equity (ROE) | -109.2% | |
| Return on Assets (ROA) | -0.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$2M |
| Free Cash Flow | -$5M |
| Total Debt | $22M |
| Debt-to-Equity | 155.6 |
| Current Ratio | 1.2 |
| Total Assets | $124M |
Price & Trading
| Last Close | $2.67 |
| 50-Day MA | $2.52 |
| 200-Day MA | $2.34 |
| Avg Volume | 82K |
| Beta | 0.3 |
|
52-Week Range
$0.95
| |
About AYTU BIOPHARMA, INC (AYTU)
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AYTU BIOPHARMA, INC (AYTU) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AYTU BIOPHARMA, INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AYTU BIOPHARMA, INC's debt ratio?
AYTU BIOPHARMA, INC's debt ratio is 80.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 17.6%.
What are AYTU BIOPHARMA, INC's key financial metrics?
AYTU BIOPHARMA, INC has a market capitalization of $28M, and revenue of $66M. The company maintains a gross margin of 66.8% and a net margin of -39.0%. Return on equity stands at -109.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.